Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs
- 26 June 2019
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (3) , 539-548
Abstract
Background and Aims: Liver function tests (alanine aminotransferase, ALT; gamma‐glutamyltransferase, GGT) not always normalize after elimination of hepatitis C virus (HCV) by direct acting antivirals (DAAs), possibly indicating concomitant non‐viral liver diseases. We analysed factors determining the biochemical response (normalized ALT/GGT) of DAA therapy in a large real‐world cohort.Method: The German Hepatitis C‐Registry is a national multicenter registry study. Normal ALT was defined ≤35 U/L (female) and ≤50 U/L (male) or, according to AASLD, ≤19 U/L (female) and ≤30 U/L (male), normal GGT ≤40 U/L (female) and ≤60 U/L (male).Results: At baseline, ALT was elevated in 3705/4946 (74.9%), ALT (AASLD) in 4669/4946 (94.4%) and GGT in 3018/4906 (61.5%). In this study, 97% of patients achieved SVR12. At week 12 after end of therapy, ALT was elevated in 451/4946 (9.1%), ALT according to AASLD in 1906/4946 (38.5%) and GGT in 863/4879 (17.7%). Persistently elevated ALT after DAA therapy was independently associated with high body mass index (BMI), age 70 years, liver cirrhosis, diabetes, alcohol consumption, opioid substitution and non‐SVR. Importantly, persistently elevated liver tests after treatment, particularly GGT, were associated with hepatic decompensation and mortality during 4‐years follow‐up.Conclusion: Risk factors at baseline (obesity, diabetes, liver cirrhosis, alcohol consumption) are independently associated with persistently elevated liver function tests after SVR, indicating that these patients warrant further hepatological follow‐up. Clinical trial registration: German Clinical Trials Register (DRKS; ID DRKS00009717).Keywords
Funding Information
- Deutsches Zentrum für Infektionsforschung
- Bristol-Myers Squibb
- Gilead Sciences
- Roche
This publication has 21 references indexed in Scilit:
- Hepatitis C virus infectionNature Reviews Disease Primers, 2017
- Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological responsePLOS ONE, 2017
- Real‐world use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infectionAlimentary Pharmacology & Therapeutics, 2017
- ACG Clinical Guideline: Evaluation of Abnormal Liver ChemistriesAmerican Journal of Gastroenterology, 2017
- The Economic Burden of Obesity in Germany: Results from the Population-Based KORA StudiesObesity Facts, 2016
- Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trialsLiver International, 2016
- AASLD guidelines for treatment of chronic hepatitis BHepatology, 2015
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2014
- Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapyHepatology International, 2012
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009